Cancer and TNF antibodies boost Biologics Sales in 2007
Epoetin alfa brands still are number one drugs with 2007 sales of US$ 5.76bln, but closely followed by (anti-TNF) etanercept with 2007 sales of US$ 5.45 bln and apositive double digit growth rate in contrast to epoetin. The Lucentis antibody fortreatment of age-related macular degeneration (AMD) has become the newestblockbuster biologic with sales higher than US$ 1 bln in 2007.
New enzyme replacementproducts explain the 2nd strongest growth by 34.1% of this class of biologic therapies.The continued double digit growth of novel insulin analogs made the class of recombinantinsulins pass the threshold of US$ 10 bln sales in 2007. These results and more were found in an an elaboration prepared by La Merie Business Intelligence and published in a complimentary report on March 27, 2008.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous